Two Sigma Investments
CADL icon

Two Sigma Investments’s Candel Therapeutics CADL Stock Holding History

Two Sigma Investments’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$458K Sell
93,500
-5,700
-6% -$31K ﹤0.01% 3789
2025
Q4 		$560K Sell
99,200
-36,916
-27% -$199K ﹤0.01% 3242
2025
Q3 		$694K Sell
136,116
-233,079
-63% -$1.35M ﹤0.01% 2813
2025
Q2 		$1.87M Buy
+369,195
New +$1.9M ﹤0.01% 1882
2024
Q2 		– Sell
-13,409
Closed -$21.2K – 3052
2024
Q1 		$21.2K Buy
+13,409
New +$19.9K ﹤0.01% 2926

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments's CADL Position: Q1 2026 in Review

Two Sigma Investments reduced its Candel Therapeutics (CADL) stake by 5.7% in Q1 2026, selling an estimated $31K and leaving 93,500 shares worth $458K. The position accounts for ﹤0.01% of the portfolio, ranked #3789.

Two Sigma Investments first reported a position in CADL in Q1 2024 and has held it in 5 quarters since. The position peaked at $1.87M in Q2 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Two Sigma Investments held 93,500 shares of Candel Therapeutics worth $458K as of Q1 2026.
  • Two Sigma Investments sold 5,700 Candel Therapeutics shares in Q1 2026, an estimated $31K.
  • Candel Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #3789 holding.
  • Two Sigma Investments first reported a position in Candel Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Two Sigma Investments's Candel Therapeutics position peaked at $1.87M in Q2 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.